Psoriasis | Eli Lilly | I1F-MC-RHCD
Pharmaceutical Company/Sponsor:
Eli Lilly
Code:
I1F-MC-RHCD
Title:
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Type:
Interventional
Phase:
3
Condition/Disease:
Psoriasis
Intervention(s)/Treatment(s):
Drug: Ixekizumab
Drug: Placebo
Drug: Etanercept
Status:
Completed
Link for Additional Information:
